American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2023
Utilization of bictegravir/emtricitabine/tenofovir alafenamide in patients with end-stage renal disease on hemodialysis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sidman Eric F, Ondrush Nicole M
Аннотация
PURPOSE: The combination antiretroviral bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is a single-tablet, once-daily regimen used in individuals living with HIV; however, its use in the context of renal impairment is uncertain. We report 6 patient cases of BIC/FTC/TAF utilization in individuals with HIV with end-stage renal disease (ESRD) requiring long-term hemodialysis (HD).
SUMMARY: These case reports describe the utilization of BIC/FTC/TAF in individuals with HIV who require chronic HD, the laboratory parameters measured, and patient-reported quality of life and adverse events.
CONCLUSION: Utilization of BIC/FTC/TAF appears to be an option for individuals with HIV who have ESRD and require long-term HD. This regimen allows for once-daily dosing, elimination of potential serious drug interactions, and simplified patient ART regimens in our patient subset.
SUMMARY: These case reports describe the utilization of BIC/FTC/TAF in individuals with HIV who require chronic HD, the laboratory parameters measured, and patient-reported quality of life and adverse events.
CONCLUSION: Utilization of BIC/FTC/TAF appears to be an option for individuals with HIV who have ESRD and require long-term HD. This regimen allows for once-daily dosing, elimination of potential serious drug interactions, and simplified patient ART regimens in our patient subset.